1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psoriasis Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Tumor Necrosis Factor Inhibitor
1.2.3 Interleukin Inhibitors
1.2.4 Others
1.3 Market by Application
1.3.1 Global Psoriasis Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Topicals
1.3.3 Systemic
1.3.4 Biologics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Psoriasis Drugs Market Perspective (2017-2028)
2.2 Psoriasis Drugs Growth Trends by Region
2.2.1 Psoriasis Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Psoriasis Drugs Historic Market Size by Region (2017-2022)
2.2.3 Psoriasis Drugs Forecasted Market Size by Region (2023-2028)
2.3 Psoriasis Drugs Market Dynamics
2.3.1 Psoriasis Drugs Industry Trends
2.3.2 Psoriasis Drugs Market Drivers
2.3.3 Psoriasis Drugs Market Challenges
2.3.4 Psoriasis Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psoriasis Drugs Players by Revenue
3.1.1 Global Top Psoriasis Drugs Players by Revenue (2017-2022)
3.1.2 Global Psoriasis Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Psoriasis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psoriasis Drugs Revenue
3.4 Global Psoriasis Drugs Market Concentration Ratio
3.4.1 Global Psoriasis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psoriasis Drugs Revenue in 2021
3.5 Psoriasis Drugs Key Players Head office and Area Served
3.6 Key Players Psoriasis Drugs Product Solution and Service
3.7 Date of Enter into Psoriasis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psoriasis Drugs Breakdown Data by Type
4.1 Global Psoriasis Drugs Historic Market Size by Type (2017-2022)
4.2 Global Psoriasis Drugs Forecasted Market Size by Type (2023-2028)
5 Psoriasis Drugs Breakdown Data by Application
5.1 Global Psoriasis Drugs Historic Market Size by Application (2017-2022)
5.2 Global Psoriasis Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Psoriasis Drugs Market Size (2017-2028)
6.2 North America Psoriasis Drugs Market Size by Country (2017-2022)
6.3 North America Psoriasis Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Psoriasis Drugs Market Size (2017-2028)
7.2 Europe Psoriasis Drugs Market Size by Country (2017-2022)
7.3 Europe Psoriasis Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psoriasis Drugs Market Size (2017-2028)
8.2 Asia-Pacific Psoriasis Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Psoriasis Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Psoriasis Drugs Market Size (2017-2028)
9.2 Latin America Psoriasis Drugs Market Size by Country (2017-2022)
9.3 Latin America Psoriasis Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psoriasis Drugs Market Size (2017-2028)
10.2 Middle East & Africa Psoriasis Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Psoriasis Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Psoriasis Drugs Introduction
11.1.4 AbbVie Revenue in Psoriasis Drugs Business (2017-2022)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Psoriasis Drugs Introduction
11.2.4 Amgen Revenue in Psoriasis Drugs Business (2017-2022)
11.2.5 Amgen Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Psoriasis Drugs Introduction
11.3.4 Johnson & Johnson Revenue in Psoriasis Drugs Business (2017-2022)
11.3.5 Johnson & Johnson Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Psoriasis Drugs Introduction
11.4.4 Novartis Revenue in Psoriasis Drugs Business (2017-2022)
11.4.5 Novartis Recent Development
11.5 Eli Lilly & Company
11.5.1 Eli Lilly & Company Company Detail
11.5.2 Eli Lilly & Company Business Overview
11.5.3 Eli Lilly & Company Psoriasis Drugs Introduction
11.5.4 Eli Lilly & Company Revenue in Psoriasis Drugs Business (2017-2022)
11.5.5 Eli Lilly & Company Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Psoriasis Drugs Introduction
11.6.4 AstraZeneca Revenue in Psoriasis Drugs Business (2017-2022)
11.6.5 AstraZeneca Recent Development
11.7 Celgene Corporation
11.7.1 Celgene Corporation Company Detail
11.7.2 Celgene Corporation Business Overview
11.7.3 Celgene Corporation Psoriasis Drugs Introduction
11.7.4 Celgene Corporation Revenue in Psoriasis Drugs Business (2017-2022)
11.7.5 Celgene Corporation Recent Development
11.8 UCB
11.8.1 UCB Company Detail
11.8.2 UCB Business Overview
11.8.3 UCB Psoriasis Drugs Introduction
11.8.4 UCB Revenue in Psoriasis Drugs Business (2017-2022)
11.8.5 UCB Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck Psoriasis Drugs Introduction
11.9.4 Merck Revenue in Psoriasis Drugs Business (2017-2022)
11.9.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
